Scarica l'app Stockscreener
0.7138
6.95%
0.0464
Dopo l'orario di chiusura:
.70
-0.0138
-1.93%
Precedente Chiudi:
$0.6674
Aprire:
$0.6933
Volume 24 ore:
1.66M
Relative Volume:
0.24
Capitalizzazione di mercato:
$44.25M
Reddito:
-
Utile/perdita netta:
$-22.83M
Rapporto P/E:
-0.9035
EPS:
-0.79
Flusso di cassa netto:
$-20.87M
1 W Prestazione:
-0.18%
1M Prestazione:
+76.25%
6M Prestazione:
+13.66%
1 anno Prestazione:
-2.03%
Intervallo 1D:
$0.6729
$0.7278
Intervallo di 1 settimana:
$0.5555
$0.75
Portata 52W:
$0.2223
$1.29
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Nome
Cognition Therapeutics Inc
Settore
Industria
Telefono
412-481-2210
Indirizzo
2403 SIDNEY STREET, PITTSBURGH
Confronta CGTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
0.7138 | 41.37M | 0 | -22.83M | -20.87M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 118.67B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.54 | 59.23B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
419.56 | 52.67B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
690.32 | 41.24B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
304.30 | 32.36B | 3.81B | -644.79M | -669.77M | -6.24 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-19 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2024-07-30 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-11-03 | Iniziato | B. Riley Securities | Buy |
| 2021-11-03 | Iniziato | Oppenheimer | Outperform |
Cognition Therapeutics Inc Borsa (CGTX) Ultime notizie
Is Cognition Therapeutics Inc. a good long term investmentCapitalize on momentum-driven stocks - Jammu Links News
What are the latest earnings results for Cognition Therapeutics Inc.Invest confidently with real-time updates - Jammu Links News
What catalysts could drive Cognition Therapeutics Inc. stock higher in 2025Superior profit margins - Jammu Links News
What makes Cognition Therapeutics Inc. stock price move sharplyMaximize returns with disciplined trading approaches - Jammu Links News
Is it the right time to buy Cognition Therapeutics Inc. stockTriple-digit returns - Jammu Links News
Why is Cognition Therapeutics Inc. stock attracting strong analyst attentionFree Daily Trading Room Entry - Jammu Links News
How volatile is Cognition Therapeutics Inc. stock compared to the marketBreakthrough capital growth - Jammu Links News
What analysts say about Cognition Therapeutics Inc. stockDynamic growth stocks - Jammu Links News
What institutional investors are buying Cognition Therapeutics Inc. stockAchieve rapid returns with smart investment plans - jammulinksnews.com
Does Cognition Therapeutics Inc. stock perform well during market downturnsGet exclusive access to premium stock research - Jammu Links News
Is Cognition Therapeutics Inc. a growth stock or a value stockValue Investing Entry Points With Proven Results - Jammu Links News
What are analysts’ price targets for Cognition Therapeutics Inc. in the next 12 monthsPost Market Recommendation With High Returns - Jammu Links News
Cognition Therapeutics’ Expanded Access Program for CT1812: A Promising Update for Investors - TipRanks
Cognition Therapeutics’ drug shows 129% cognitive decline arrest in mild Alzheimer’s - Yahoo Finance
Published on: 2025-07-29 20:05:06 - metal.it
Applying sector rotation models to Cognition Therapeutics Inc.Long Hold Safe Return Strategy Reviewed - metal.it
New Data: Zervimesine for the Treatment of Dementia With Lewy Bodies and Alzheimer Disease - Psychiatric Times
How high can Cognition Therapeutics Inc. stock price go in 2025Conservative Long Term Growth Plans Under Review - metal.it
Cognition Therapeutics Presents Data at AAIC Highlighting - GlobeNewswire
Breakthrough Drug Zervimesine Halts Alzheimer's Decline by 129%, Shows Promise in Lewy Body Dementia - Stock Titan
Cognition Therapeutics shares rise 3.50% premarket after PTC Therapeutics' FDA approval of Sephience. - AInvest
What drives Cognition Therapeutics Inc. stock priceExceptional profit velocity - PrintWeekIndia
Cognition Therapeutics Inc. Stock Analysis and ForecastStrong return on investment - Autocar Professional
Cognition Therapeutics Publishes Proteomic Analysis - GlobeNewswire
Cognition Therapeutics reports positive results for Alzheimer’s drug By Investing.com - Investing.com South Africa
Cognition Therapeutics Publishes Phase 2 Study Results of Zervimesine for Alzheimer's Disease in Alzheimer's & Dementia Journal - Nasdaq
Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease - The Manila Times
Cognition Therapeutics Inc Azioni (CGTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):